Clinical trial · Interventional
Low to Moderate Load Power Training for Men With Metastatic Prostate Cancer.
Low to Moderate Load Power Training as an Exercise Intervention for Men With Metastatic Prostate Cancer Undergoing Androgen Deprivation Therapy.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to learn if a low to moderate load power training program is feasible and effective for improving fitness and quality of life of people with prostate cancer under androgen suppression therapy and bone or lymph node metastasis. The main questions it aims to answer are: * Does a low to moderate load power training program improve quality of life in people with metastatic prostate cancer under androgen deprivation therapy? * Does a low to moderate load power training program improve power, strength, endurance, and balance in people with metastatic prostate cancer under androgen deprivation therapy? Researchers will compare the exercise program with routine care to see if power training works to improve common physical side effects of androgen suppression therapy in patients with metastatic prostate cancer. Participants will: * Participate in a supervised exercise program twice a week for 6 months or maintain routine care. * Perform fitness tests and questionnaires about quality of life and mental health. * Those who take part in the exercise program will also perform semi-structured in-depth interviews after the end of the program.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostatic Neoplasms | Prostate Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Power training group | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Power training group
- description
- The intervention consists of a supervised power-oriented resistance training program for older men with metastatic prostate cancer undergoing androgen deprivation therapy (ADT). Participants will complete 2 sessions per week over 24 weeks. Training focuses on improving muscle power through exercises performed at moderate intensity (40-50% 1RM), emphasizing a fast concentric phase and controlled eccentric phase. Multi-joint functional exercises targeting major muscle groups are included to enhance strength, balance, and daily functional performance. Training volume is low-to-moderate, and participants do not train to muscular failure, allowing maintenance of movement velocity and reducing fatigue. Adequate rest periods are provided between sets. The program is adapted to the clinical characteristics of the population, minimizing mechanical stress while promoting neuromuscular improvements. It is designed to be safe, feasible, and well-tolerated.
- interventionNames
- Other: Power training group
- type
- NO_INTERVENTION
- label
- Control group
- description
- Participants will continue with their usual care and will receive standardized information and guidance on how to remain physically active at home.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * Histopathologically confirmed diagnosis of prostate adenocarcinoma. • Metastatic hormone-sensitive prostate cancer (mHSPC), defined as: * Presence of metastases at initial diagnosis (synchronous mHSPC), or * Development of metastatic disease following prior treatment with curative intent (surgery and/or radiotherapy) (metachronous mHSPC). * Evidence of progression to castration-resistant prostate cancer (CRPC). * Ongoing treatment with a doublet regimen consisting of standard androgen deprivation therapy (ADT) in combination with an androgen receptor signaling inhibitor (ARSI), initiated prior to study enrollment. * Receipt of bone-protective therapy, including calcium and vitamin D supplementation in combination with bisphosphonates. * Presence of metastatic involvement limited to bone and/or lymph nodes. * Functionally independent in activities of daily living. Exclusion Criteria: * Evidence of visceral metastatic disease. * Current or prior treatment with a triplet regimen that includes chemotherapy. * History of pathological fracture.
References
Publications (22)
- BACKGROUNDAagaard P, Simonsen EB, Andersen JL, Magnusson P, Dyhre-Poulsen P. Neural adaptation to resistance training: changes in evoked V-wave and H-reflex responses. J Appl Physiol (1985). 2002 Jun;92(6):2309-18. doi: 10.1152/japplphysiol.01185.2001. PMID 12015341
- BACKGROUNDBassyouny NM, Gouda MM, Ezz El Din MM, Sweed HS, El Akkad RM. Impact of Androgen Deprivation Therapy on Cognitive Function of Elderly Men With Prostate Cancer. Cureus. 2024 Sep 12;16(9):e69303. doi: 10.7759/cureus.69303. eCollection 2024 Sep. PMID 39398693
- BACKGROUNDBigaran A, Zopf E, Gardner J, La Gerche A, Murphy DG, Howden EJ, Baker MK, Cormie P. The effect of exercise training on cardiometabolic health in men with prostate cancer receiving androgen deprivation therapy: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2021 Mar;24(1):35-48. doi: 10.1038/s41391-020-00273-5. Epub 2020 Aug 28. PMID 32860010
- BACKGROUNDCormie P, Turner B, Kaczmarek E, Drake D, Chambers SK. A qualitative exploration of the experience of men with prostate cancer involved in supervised exercise programs. Oncol Nurs Forum. 2015 Jan;42(1):24-32. doi: 10.1188/15.ONF.24-32. PMID 25542318
- BACKGROUNDEl Hadouchi M, Kiers H, Veenhof C, Van Dieen J. The Impact of Power Training on Muscle Power, Physical Performance, and Physical Functioning in Older Adults: A Descriptive Case Series. Clin Interv Aging. 2025 Jun 16;20:849-857. doi: 10.2147/CIA.S511954. eCollection 2025. PMID 40547363
- BACKGROUNDGardner JR, Livingston PM, Fraser SF. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol. 2014 Feb 1;32(4):335-46. doi: 10.1200/JCO.2013.49.5523. Epub 2013 Dec 16. PMID 24344218
- BACKGROUNDLopez P, Taaffe DR, Newton RU, Buffart LM, Galvao DA. What is the minimal dose for resistance exercise effectiveness in prostate cancer patients? Systematic review and meta-analysis on patient-reported outcomes. Prostate Cancer Prostatic Dis. 2021 Jun;24(2):465-481. doi: 10.1038/s41391-020-00301-4. Epub 2020 Nov 20.